Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus

(Updated - July 24, 2018 6:39 AM EDT)

Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.80, $0.56 better than the analyst estimate of $5.24. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $3.26 billion.

GUIDANCE:

Biogen sees FY EPS of $24.90-$25.50 vs $24.01 consensus. FY2018 revenue of $13-13.2 billion, versus the consensus of $12.98 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
• FactSet Research Systems (FDS) PT Raised to $253 at Jefferies